

**August 13, 2021**

**Viatis Inc. Report on U.S. Opioid Abuse**

) was formed through a

worldwide to live healthier at every stage of life. The Company provides access to medicines, advances sustainable operations, develops innovative solutions and leverages its collective expertise to improve patient health. As part of its mission, Viatis is committed to addressing pressing public health issues, and the challenges pertaining to opioid abuse in the U.S. is no exception.

Board of Directors supports publication of this report to provide shareholders and other stakeholders with relevant details pertaining to help in the nationwide fight against opioid addiction, abuse, and misuse.

**I. Viatis' Opioid**

important therapeutic benefits for appropriate patient populations, when prescribed and used responsibly.

## **II. Comprehensive Responses to Help Fight Opioids Abuse**

### a. \_\_\_\_\_-Opioid Products

Given its extensive scientific capabilities, the Company is taking a leading role in finding pharmaceutical solutions to combat opioid addiction, misuse, and abuse. As the FDA has recognized, steps taken to confront th

efforts include physical security controls and employee screening programs which comply with the federal Controlled Substances Act (CSA) and DEA regulations at all locations where controlled substances are held. The physical security controls for Viatris facilities receive advance approval by the relevant local DEA offices prior to implementation at the facilities.

Viatris also has designed and operates a system to identify suspicious orders of controlled substances consistent with federal regulatory obligations. We have a cross-functional team including members from Compliance, Customer Relations, Controlled Substance Monitoring, Global Security, Distribution Center, Regulatory Legal, Regulatory Affairs, State Licensing and DEA that works to vet customers and orders, and maintain and continuously enhance our strong programs designed to detect and prevent diversion within the supply chain.

For example, the Company has established a suspicious order monitoring (SOM) system that consists of internal controls to identify suspicious orders and prevent the sale of controlled substances, including opioid-containing products, where there may be a risk of diversion. For example:

- Orders for controlled substances, including opioid products, are not sent for distribution center processing until they are approved for release.
- Order information for controlled substances is transmitted to the SOM system, which performs statistical modeling calculations to identify potential suspicious orders. A suspicious order of a controlled substance may include, but is not limited to, an order of unusual size or deviating substantially from a normal pattern, and orders of unusual frequency.
- If the statistical modeling needing additional review, the order is placed on hold and will not be shipped unless the order is deemed to not be suspicious after investigation.
- Orders flagged by trained Controlled Substance Monitoring Team (CSMT) and, if needed, routed to the Regulatory Affairs/DEA Compliance Team for further consideration and resolution.

SOM processes are set forth in clear, comprehensive written policies and Standard Operating Procedures (SOP) that outline the purpose and scope of the SOM program and relevant employee responsibilities. Applicable Company personnel are required to complete training on the SOM Program and to understand the importance of DEA compliance.



ii. Code of Business Conduct and Ethics

More broadly, operations are governed by a Code of Business Conduct and Ethics, also known as the Code, which is administered by the Compliance Department. It is a condition of employment that Viatris employees comply with the Code and the applicable laws of the countries in which Viatris does business. Viatris employees receive annual training on the Code and must periodically certify that they have read the Code and will, to the best of their knowledge and belief, comply with the Code. Among other obligations, the Code requires adherence to current good manufacturing and good laboratory practices, prompt reporting of concerns regarding product quality and adverse events, and compliance with established internal controls. The Company, at its sole discretion, may take action including termination of employment or preventing participation compensation program against anyone for violating the Code, applicable law, or Company policy.

iii. Interactions with Healthcare Providers and Promotional Activities

Viatris is not promoting or marketing any of its opioid products. As a matter of global corporate policy, Code requires that promotional activities and materials must comply with all applicable laws, regulations and codes, and own marketing and advertising review policies, and must be truthful, accurate, not misleading, consistent with

With respect to investigating, resolving and remediating reported events, our Global Policy on Reporting and Investigating Compliance-Related Matters outlines a clear process that includes a thorough, impartial and timely investigation of each report in coordination with Human Relations, our Legal Department and other functions as appropriate; and fair and consistent disciplinary measures, when necessary. In addition, Viartis considers any appropriate policy and procedure changes in connection with its investigations.

### **III. Board Engagement and Executive Compensation Related to Opioids**

#### a. Board-Level Committees





